INS and pancreatic neoplasm: Hazard Ratios (HRs) for the Association of Pancreatic Cancer With 1 Defined Daily Dose (DDD) Increment in Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Use vs 1 DDD Increment in Basal Insulin Use During the 7 Years Before Cancer Diagnosisa